Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Haroon Majoka

Neurology Bowling Green, KY Medical Doctor

NPI 1437682978 CMS profile 7232188

350 Park St Ste 206, Bowling Green, KY 42101

Open in the dashboard

General payments

$5,497

303 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Haroon Majoka of Bowling Green, KY is reported in the CMS Open Payments database as having received $5,497 across 303 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,102 124
2024 General $2,268 122
2023 General $1,075 54
2021 General $13 1
2019 General $40 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Haroon Majoka
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Haroon Majoka were reported at $2,102. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Haroon Majoka Neurology median Middle half National median
2019 $40 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $13 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $1,075 $464 $119–$2,312 $160
2024 $2,268 $468 $119–$2,323 $164
2025 $2,102 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $723 60 payments
  2. Pfizer Inc. $695 53 payments
  3. Neurocrine Biosciences, Inc. $511 20 payments
  4. UCB, Inc. $498 18 payments
  5. Biogen, Inc. $296 17 payments
  6. Catalyst Pharmaceuticals, Inc. $261 11 payments
  7. Jazz Pharmaceuticals Inc. $227 11 payments
  8. Teva Pharmaceuticals USA, Inc. $223 13 payments
  9. CSL Behring $223 13 payments
  10. Alexion Pharmaceuticals, Inc. $208 4 payments
  11. Other $1,634 83 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,347 301 payments
  2. Education $150 2 payments
Products named General payments · program years 2019–2025
  1. NURTEC ODT $695 53 payments
  2. ZAVZPRET $695 53 payments
  3. QULIPTA $542 48 payments
  4. UBRELVY $520 46 payments
  5. INGREZZA $511 20 payments
  6. Briviact $269 11 payments
  7. FYCOMPA $235 10 payments
  8. Epidiolex $227 11 payments
  9. Austedo XR $223 13 payments
  10. Hizentra $223 13 payments
  11. Other $2,311 117 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

1,546

Median for Neurology: 833

Drug cost

$311,207

Median for Neurology: $202,670

Branded share of claims

24.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 11 $163,429
Ajovy Autoinjector Fremanezumab-Vfrm Brand 32 $30,683
Qulipta Atogepant Brand 17 $21,610
Ubrelvy Ubrogepant Brand 21 $21,494
Aimovig Autoinjector Erenumab-Aooe Brand 11 $16,714
Emgality Pen Galcanezumab-Gnlm Brand 22 $14,630
Nurtec Odt Rimegepant Sulfate Brand 13 $13,256
Rytary Carbidopa/Levodopa Brand 11 $5,594
Lacosamide Generic 53 $3,197
Primidone Generic 89 $2,386

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$24,906

Medicare's payments for the services billed

Medicare patients

215

Average age 74

Services billed

400

114 women, 101 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 42%
Depression 42%
Diabetes 40%
Heart failure 32%
Chronic kidney disease 32%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $202
$202 — —
Briviact
  • UCB, Inc. $182
$182 — —
NURTEC ODT
  • PFIZER INC. $151
$151 13 —
ZAVZPRET
  • PFIZER INC. $151
$151 — —
QULIPTA
  • AbbVie, Inc. $131
$131 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

303 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record